Merck & Co has said it will not file anacetrapib with regulators
BMS’ rival anticoagulant takes commanding market lead.
Diabetes drug has been hit by amputation warning on label.
Cardioprotective effect occurred in patients independently of blood sugar control
Heart Rate app will feature in FDA and Stanford study.
Deep learning AI analyses retinal images to determine heart disease risk.
A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients.
Label gives guidance in use when restoring normal heart rhythm
New tool will help screen for Long QT syndrome to prevent sudden deaths.